
Last updated: 2026-09-16 09:04:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Kardigan, Inc. (KARD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18.55, with a market capitalisation of $1.78B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.25 to $27.00. This page covers its latest market performance, valuation, price trends and company information.
$1.78B | |
$18.95 | |
$27.00 | |
$16.25 | |
$19.05 | |
315.58K | |
449.09K | |
-- | |
$27.00 | |
$16.25 | |
-- | |
-- |
Kardigan, Inc. (KARD) is trading at $18.54 in pre-market trading as of 2026-09-15 23:31:00, down 2.68% ($0.51) from the previous close of $19.05
Pre-market trading shows how investors are pricing KARD before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Kardigan, Inc. (KARD) moved from $20.85 to $18.55, representing a decline of 11.05% ($2.30).
The stock traded between $17.77 and $22.05 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 457.37 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 21.4%
KARD is currently trading at $18.55, placing it 21.4% of the way from its 52-week low of $16.25 to its 52-week high of $27.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kardigan, Inc. (KARD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.